FY2030 Earnings Estimate for ZNTL Issued By HC Wainwright

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Zentalis Pharmaceuticals in a report issued on Friday, March 27th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($0.06) for the year. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share.

Several other research firms have also recently commented on ZNTL. Guggenheim reaffirmed a “buy” rating and issued a $6.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, March 27th. Wall Street Zen cut Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Wells Fargo & Company began coverage on Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $5.17.

Zentalis Pharmaceuticals Stock Up 9.3%

ZNTL stock opened at $2.34 on Monday. Zentalis Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $3.95. The company has a market cap of $165.98 million, a PE ratio of -1.23 and a beta of 1.71. The business’s 50-day simple moving average is $2.54 and its 200 day simple moving average is $1.96.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.08).

Insiders Place Their Bets

In related news, insider Vincent Vultaggio sold 29,951 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the transaction, the insider owned 156,779 shares of the company’s stock, valued at $380,972.97. This represents a 16.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 46,617 shares of company stock valued at $113,417 over the last quarter. Insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC boosted its stake in Zentalis Pharmaceuticals by 35.3% in the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock valued at $48,000 after acquiring an additional 8,236 shares during the last quarter. Invesco Ltd. raised its position in shares of Zentalis Pharmaceuticals by 8.6% during the 4th quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock valued at $255,000 after acquiring an additional 14,961 shares during the last quarter. Barr E S & Co. lifted its stake in shares of Zentalis Pharmaceuticals by 43.8% in the 4th quarter. Barr E S & Co. now owns 57,500 shares of the company’s stock valued at $78,000 after purchasing an additional 17,500 shares during the period. Vanguard Group Inc. lifted its stake in shares of Zentalis Pharmaceuticals by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock valued at $4,386,000 after purchasing an additional 19,768 shares during the period. Finally, Sivia Capital Partners LLC bought a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth $27,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.